Table 2.
Risk of antiphospholipid syndrome exposed to psoriasis compared to non-psoriasis.
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| N | No. of event | HR (95% C.I.) | N | No. of event | HR (95% C.I.) | |
| Group | ||||||
| Non-Psoriasis | 8,425,385 | 1,352 | Reference | 288,678 | 673 | Reference |
| Psoriasis | 292,106 | 1,352 | 1.88 (1.78–1.99) | 288,678 | 1,349 | 1.71 (1.56–1.88) |
| Group | ||||||
| Non-Psoriasis | 8,079,123 | 16,110 | Reference | 64,912 | 157 | Reference |
| Psoriatic arthritis | 69,227 | 348 | 2.13 (1.91–2.37) | 64,912 | 340 | 1.91 (1.58–2.31) |
PSM, propensity score matching; HR, hazard ratio; CI, confidence interval.